BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 260.04M | 295.09M | 320.85M | 330.01M | 272.03M |
Total Receivables | 91.18M | 93.39M | 79.07M | 72.46M | 68.76M |
Inventory | 5.04M | 6.87M | 8.09M | 7.56M | 4.45M |
Prepaid Expenses | 12.54M | 14.33M | 13.75M | 16.28M | 16.43M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 29.66M | 291.00K | 210.00K | 813.00K | 1.80M |
Total Current Assets | 398.46M | 409.98M | 421.97M | 427.13M | 363.46M |
|
|||||
Total Current Assets | 398.46M | 409.98M | 421.97M | 427.13M | 363.46M |
Net Property, Plant & Equipment | 20.00M | 19.58M | 19.79M | 19.63M | 19.85M |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 28.62M | 29.95M | 28.34M | 25.07M | 24.79M |
Total Assets | 457.19M | 480.05M | 490.42M | 491.25M | 472.42M |
|
|||||
Total Accounts Payable | 8.59M | 10.05M | 11.64M | 13.48M | 7.79M |
Total Accrued Expenses | 107.11M | 92.64M | 113.29M | 104.20M | 89.60M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 37.75M | 37.17M | 35.45M | 35.89M | 31.68M |
Total Finance Division Other Current Liabilities | 23.71M | -- | -- | -- | -- |
Total Other Current Liabilities | 23.71M | -- | -- | -- | -- |
Total Current Liabilities | 177.16M | 139.86M | 160.38M | 153.57M | 129.07M |
|
|||||
Total Current Liabilities | 177.16M | 139.86M | 160.38M | 153.57M | 129.07M |
Long-Term Debt | 690.64M | 782.03M | 795.92M | 796.11M | 808.48M |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 10.53M | 10.09M | 10.05M | 10.14M | 10.48M |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 454.00K | -- | -- | -- | -- |
Total Liabilities | 878.78M | 931.97M | 966.35M | 959.82M | 948.03M |
|
|||||
Common Stock & APIC | 1.34B | 1.32B | 1.29B | 1.27B | 1.25B |
Retained Earnings | -1.76B | -1.77B | -1.77B | -1.74B | -1.73B |
Treasury Stock & Other | 1.65M | 1.13M | 921.00K | 2.29M | 557.00K |
Total Common Equity | -421.59M | -451.93M | -475.93M | -468.56M | -475.61M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | -421.59M | -451.93M | -475.93M | -468.56M | -475.61M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | -421.59M | -451.93M | -475.93M | -468.56M | -475.61M |
|